A
American Oriental Bioengineering Inc. Stock Analysis AOBI
United States Consumer Staples Nano Cap American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of pharmaceutical and healthcare products. The firm is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Nutraceutical products are intended for the overall well-being. The firm also sells several nutraceutical products, including its soybean peptide-based drinks, tablets, powder and instant coffee.
Read More American Oriental Bioengineering Inc (AOBI) Chart
Key Statistics of American Oriental Bioengineering Inc (AOBI)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
500.00P/E Ratio (TTM)
-52 Week Range
Market Cap
87.60Avg. Volume
500.00Dividend Yield
-Financial Metrics & Statements of American Oriental Bioengineering Inc (AOBI)
FAQ's for American Oriental Bioengineering Inc (AOBI)
- According to Musaffa’s Shariah screening methodology, American Oriental Bioengineering Inc (AOBI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.